Acta Diabetologica

, Volume 49, Issue 4, pp 301–305

Structural damage in diabetic nephropathy is associated with TNF-α system activity

  • José Manuel Fernández-Real
  • Joan Vendrell
  • Isabel García
  • Wifredo Ricart
  • Martí Vallès
Original Article


In experimental animal studies, tumour necrosis factor-α (TNF-α) contributed to renal hypertrophy during diabetes, and antibodies against TNF-α have led to improved histological lesions in animals with nephrotoxicity and diabetic nephropathy. We aimed to evaluate TNF-α system activity in association with renal histology in patients with type 2 diabetes. This is a prospective, cross-sectional study of 22 patients with type 2 diabetes (16 men), 13 with microalbuminuria and 9 with normoalbuminuria. Plasma-soluble TNF-α receptor 1 and 2 (sTNFR1 and sTNFR2) concentrations were used as surrogates of TNF-α system activity. Glomerular filtration rate (GFR) was analysed using I125-Iodothalamine. Albumin excretion rate (AER) and a renal biopsy were performed in all subjects. AER did not associate significantly with mesangial expansion or interstitial fraction in these subjects (r < 0.12, P > 0.5). AER was also not associated with either sTNFR1 or sTNFR2 levels. However, after controlling for GFR, the correlation between AER and sTNFR1 became significant (r = 0.47, P = 0.03). sTNFR1 correlated with age (r = 0.65, P < 0.001), mesangial expansion (r = 0.59, P = 0.004) and interstitial fraction (r = 0.58, P = 0.005). After controlling for age, body mass index and blood pressure, the association of TNFR1 with mesangial expansion persisted significant. Circulating sTNFR2 concentrations were not significantly associated with histological changes. In summary, structural kidney damage in patients with type 2 diabetes is associated with TNF-α system activity and specifically with plasma sTNFR1 concentrations.


Inflammation TNF system Type 2 diabetes Diabetic nephropathy Renal histology 


  1. 1.
    Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922Google Scholar
  2. 2.
    Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012PubMedCrossRefGoogle Scholar
  3. 3.
    Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548PubMedCrossRefGoogle Scholar
  4. 4.
    Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118CrossRefGoogle Scholar
  5. 5.
    Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463PubMedCrossRefGoogle Scholar
  6. 6.
    Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34Google Scholar
  7. 7.
    Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324PubMedCrossRefGoogle Scholar
  8. 8.
    Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762PubMedCrossRefGoogle Scholar
  9. 9.
    Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print)Google Scholar
  10. 10.
    Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print)Google Scholar
  11. 11.
    Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print)Google Scholar
  12. 12.
    Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142PubMedCrossRefGoogle Scholar
  13. 13.
    Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394PubMedCrossRefGoogle Scholar
  14. 14.
    Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410PubMedGoogle Scholar
  15. 15.
    Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329PubMedCrossRefGoogle Scholar
  16. 16.
    Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642PubMedCrossRefGoogle Scholar
  17. 17.
    Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697PubMedCrossRefGoogle Scholar
  18. 18.
    DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121PubMedGoogle Scholar
  19. 19.
    Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962PubMedCrossRefGoogle Scholar
  20. 20.
    Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552PubMedGoogle Scholar
  21. 21.
    Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232PubMedCrossRefGoogle Scholar
  22. 22.
    Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636PubMedCrossRefGoogle Scholar
  23. 23.
    Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51PubMedCrossRefGoogle Scholar
  24. 24.
    Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218PubMedCrossRefGoogle Scholar
  25. 25.
    Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672PubMedCrossRefGoogle Scholar
  26. 26.
    Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546PubMedCrossRefGoogle Scholar
  27. 27.
    Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • José Manuel Fernández-Real
    • 1
  • Joan Vendrell
    • 2
  • Isabel García
    • 3
  • Wifredo Ricart
    • 1
  • Martí Vallès
    • 3
  1. 1.Department of Diabetes, Endocrinology and Nutrition, and CIBEROBN Fisiopatología de la Obesidad y NutriciónUniversity Hospital of Girona “Dr. Josep Trueta”GironaSpain
  2. 2.Unitat de Endocrinologia i Nutrició, University Hospital of Tarragona “Joan XXIII”, and CIBERDEMTarragonaSpain
  3. 3.Servei de Nefrologia, University Hospital of Girona “Dr. Josep Trueta”GironaSpain

Personalised recommendations